within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB14_SebelipaseAlfa;
model SebelipaseAlfa 
   extends Pharmacolibrary.Drugs.ATC.A.A16AB14;

  annotation(Documentation(
    info ="<html><body><p>Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme replacement therapy indicated for the treatment of lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder causing the accumulation of cholesteryl esters and triglycerides. It is approved for use in both pediatric and adult patients with LAL-D.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult and pediatric (≥8 years) patients with LAL-D receiving intravenous sebelipase alfa at a dose of 1 mg/kg; values are geometric mean population PK model parameters from the published study.</p><h4>References</h4><ol><li><p>Shirley, M (2015). Sebelipase alfa: first global approval. <i>Drugs</i> 75(16) 1935–1940. DOI:<a href=&quot;https://doi.org/10.1007/s40265-015-0479-6&quot;>10.1007/s40265-015-0479-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26452566/&quot;>https://pubmed.ncbi.nlm.nih.gov/26452566</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end SebelipaseAlfa;
